Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Understanding what to avoid when investing in crypto is crucial for success. Make informed decisions to protect your wealth with our insights.
18,150 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A surge in triple-leveraged ETFs has driven notional exposure to about $500 billion, intensifying daily volatility an...
A famous AI investor argues the economics of AI deployment could shift cash flow toward infrastructure vendors like N...
Citigroup is up about 14% year-to-date through mid-July 2026, outpacing Bank of America and Wells Fargo. AI-driven tr...
Choosing between VEA and NZAC boils down to your priority: broad diversification in developed markets or a climate-al...
As retirees balance work and benefits, the earnings test remains a key lever. The 2026 threshold of $65,160 shapes ho...
A timely look at how independent journalism survives in 2026, focusing on Amy Goodman and the economics of free‑press...
Rocket Lab’s stock has faced renewed pressure as the market weighs contracting demand signals and execution risks. Th...
Procter & Gamble has built a remarkable dividend-growth legacy, raising payouts for seven decades. This article break...
A viral comparison claims pokémon cards beat 2.5x the S&P 500 over two decades, but analysts warn that rising fees, i...
A bold move from Rocket Lab could shift the balance in space infrastructure. This analysis breaks down the deal, its ...
Lauren Sánchez Bezos is fueling a $34 million Bezos Earth Fund push to reinvent fabrics—from bacteria-grown fibers to...